GYRE (Gyre Therapeutics) Pre-Tax Income : $23.2 Mil (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Gyre Therapeutics's pretax income for the three months ended in Dec. 2024 was $0.8 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $23.2 Mil. Gyre Therapeutics's pretax margin was 2.77%.

During the past 4 years, Gyre Therapeutics's highest Pretax Margin was 33.05%. The lowest was -67.84%. And the median was 15.58%.

Gyre Therapeutics Pre-Tax Income Historical Data

The historical data trend for Gyre Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Pre-Tax Income Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Pre-Tax Income

29.61

9.41

-76.97

23.22

Gyre Therapeutics Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Pre-Tax Income	Get a 7-Day Free Trial						-100.28	12.48	6.04	3.93	0.77

Competitive Comparison of Gyre Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Gyre Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gyre Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Gyre Therapeutics's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Gyre Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Gyre Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	16.229	+	5.442	+	0	+	1.547	+	0
	=	23.2

Gyre Therapeutics's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	0.663	+	-0.237	+	0	+	0.346	+	0
	=	0.8

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $23.2 Mil.

Gyre Therapeutics (NAS:GYRE) Pre-Tax Income Explanation

Gyre Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	0.772	/	27.872
	=	2.77%

During the past 4 years, Gyre Therapeutics's highest Pretax Margin was 33.05%. The lowest was -67.84%. And the median was 15.58%.

Gyre Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.